Clinicopathological significance of metallothioneins in breast cancer
Tóm tắt
Từ khóa
Tài liệu tham khảo
Kojima Y, Binz P-A, Kagi JHR: Nomenclature of metallothionein: proposal for a revision. In: Klaassen, C.D. eds. Metallothionein IV, Birkhauser Verlag, Basel, Switzerland. pp 3–6, 1999.
Pande J, Vasak M, Kagi JH: Interaction of lysine residues with the metal thiolate clusters in metallothionein. Biochemistry 24: 6717–6722, 1985.
Robbins AH, McRee DE, Williamson M, et al.: Refined crystal structure of Cd, Zn metallothionein at 2.0Å resolution. J Mol Biol 221: 1269–1293, 1991.
Binz P-A, Kagi JHR: Metallothionein: molecular evolution and classification. In: Klaassen, C.D. eds. Metallothionein IV, Birkhauser Verlag, Basel, Switzerland. pp 7–13, 1999.
West AK, Stallings R, Hildebrand CE, et al.: Human metallothionein genes: structure of the functional locus at 16q13. Genomics 8: 513–518, 1990.
Stennard FA, Holloway AF, Hamilton J, et al.: Characterisation of six additional human metallothionein genes. Biochim Biophys Acta 1218: 357–365, 1994.
Mididoddi S, McGuirt JP, Sens MA, et al.: Isoform-specific expression of metallothionein mRNA in the developing and adult human kidney. Toxicol Lett 85:17–27, 1996.
Palmiter RD, Findley SD, Whitmore TE, et al.: MT-III, a brainspecific member of the metallothionein gene family. Proc Natl Acad Sci USA 89: 6333–6337, 1992.
Quaife CJ, Findley SD, Erickson JC, et al.: Induction of a new metallothionein isoform (MT-IV) occurs during differentiation of stratified squamous epithelia. Biochemistry 33: 7250–7259, 1994.
Braun W, Wagner G, Worgotter E, et al.: Polypeptide fold in the two metal clusters of metallothionein-2 by nuclear magnetic resonance in solution. J Mol Biol 187: 125–129, 1986
Schultze P, Worgotter E, Braun W, et al.: Conformation of [Cd7]-metallothionein-2 from rat liver in aqueous solution determined by nuclear magnetic resonance spectroscopy. J Mol Biol 203: 251–268, 1988
Braun W, Vasak M, Robbins AH et al.: Comparison of the NMR solution structure and the X-ray crystal structure of rat metallothionein-2. Proc Natl Acad Sci USA 89: 10124–10128, 1992.
Tapiero H, Tew KD: Trace elements in human physiology and pathology: zinc and metallothioneins. Biomed Pharmacother 57: 399–411, 2003.
Roesijadi G. Metal transfer as a mechanism for metallothioneinmediated metal detoxification. Cell Mol Biol (Noisy-legrand) 46: 393–405, 2000.
Kagi JH, Kojima Y. Chemistry and biochemistry of metallothionein. Experientia 52: 25–61, 1987.
Kondoh M, Imada N, Kamada K, et al.: Property of metallothionein as a Zn pool differs depending on the induced condition of metallothionein. Toxicol Lett 142: 11–18, 2003.
Maret W: Metallothionein/disulfide interactions, oxidative stress, and mobilization of cellular zinc. Neurochem Int 27: 111–117, 1995.
Maret W, Vallee BL: Thiolate ligands in metallothionein confer redox activity on zinc clusters. Proc Natl Acad Sci USA 95: 3478–3482, 1998.
Miura T, Muraoka S, Ogiso T: Antioxidant activity of metallothionein compared with reduced glutathione. Life Sci 60: 301–309, 1997.
Hussain S, Slikken JW, Ali SF. Role of metallothionein and the antioxidants in scavenging superoxide radicals and their possible role in neuroprotection. Neurol Chem Int 29: 145–152, 1996.
Abel J, Ruiter N: Inhibition of hydroxy radical generated DNA degradation by metallothionein. Toxicol Lett 47: 191–196, 1989.
Cai L, Klein JB, Kang YJ: Metallothionein inhibits peroxynitriteinduced DNA and lipoprotein damage. J Biol Chem 275: 38957–38960, 2000.
Mendez-Armenta M, Villeda-Hernandez J, Barroso-Moguel R, et al.: Brain regional lipid peroxidation and metallothionein levels of developing rats exposed to cadmium and dexamethasone. Toxicol Lett 144: 151–157, 2003.
Garrett SH, Sens MA, Shukla D, et al.: Metallothionein isoform 1 and 2 gene expression in the human prostate: downregulation of MT-1X in advanced prostate cancer. Prostate 43: 125–135, 2000.
Tai SK, Tan OJ, Chow VT, et al.: Differential expression of metallothionein 1 and 2 isoforms in breast cancer lines with different invasive potential: identification of a novel nonsilent metallothionein-1H mutant variant. Am J Pathol 163: 2009–2019, 2003.
Haq F, Mahoney M, Koropatnick J: Signaling events for metallothionein induction. Mutat Res 533: 211–226, 2003.
Garrett SH, Somji S, Todd JH, et al.: Differential expression of human metallothionein isoform I mRNA in human proximal tubule cells exposed to metals. Environ Health Perspect 106: 825–832, 1998.
Garrett SH, Belcastro M, Sens MA, et al.: Acute exposure to arsenite induces metallothionein isoform-specific gene expression in human proximal tubule cells. J Toxicol Environ Health A 64: 343–355, 2001.
Jahroudi N, Foster R, Price-Haughey J, et al.: Cell-type specific and differential regulation of the human metallothionein genes. Correlation with DNA methylation and chromatin structure. J Biol Chem 265: 6506–6511, 1990.
Barnes NL, Ackland ML, Cornish EJ: Metallothionein isoform expression by breast cancer cells. Int J Biochem Cell Biol 32: 895–903, 2000.
Fresno M, Wu W, Rodriguez JM, et al.: Localization of metallothionein in breast carcinomas. An immunohistochemical study. Virchows Arch A Pathol Anat Histopathol 423: 215–219, 1993.
Jin R, Bay BH, Chow VT, et al.: Significance of metallothionein expression in breast myoepithelial cells. Cell Tissue Res 303: 221–226, 2001.
Bier B, Douglas-Jones A, Totsch M, et al.: Immunohistochemical demonstration of metallothionein in normal human breast tissue and benign and malignant breast lesions. Breast Cancer Res Treat 30: 213–221, 1994.
Schmid KW, Ellis IO, Gee JM, et al.: Presence and possible significance of immunocytochemically demonstrable metallothionein over-expression in primary invasive ductal carcinoma of the breast. Virchows Arch A Pathol Anat Histopathol 422: 153–159, 1993.
Zhang R, Zhang H, Wei H, et al.: Expression of metallothionein in invasive ductal breast cancer in relation to prognosis. J Environ Pathol Toxicol Oncol 19: 95–97, 2000.
Vazquez-Ramirez FJ, Gonzalez-Campora JJ, Hevia-Alvarez E, et al.: P-glycoprotein, metallothionein and NM23 protein expressions in breast carcinoma. Pathol Res Pract 196: 553–559, 2000.
Jin R, Chow VT, Tan PH, et al.: Metallothionein 2A expression is associated with cell proliferation in breast cancer. Carcinogenesis 23: 81–86, 2002.
Ioachim E, Tsanou E, Briasoulis E, et al.: Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer. Breast 12: 111–119, 2003.
Jin R, Bay BH, Chow VTK, et al.: Metallothionein 1F mRNA expression correlates with histological grade in breast carcinoma. Breast Caner Res Treat 66: 265–272, 2001.
Sens MA, Somji S, Garrett SH, et al.: Metallothionein isoform 3 overexpression is associated with breast cancers having a poor prognosis. Am J Pathol 159: 21–26, 2001.
Nartey N, Cherian MG, Banerjee D: Immunohistochemical localization of metallothionein in human thyroid tumors. Am J Pathol 129: 177–182, 1987
Cherian MG, Huang PC, Klaassen CD, et al.: National Cancer Institute workshop on the possible roles of metallothionein in carcinogenesis. Cancer Res 53: 922–925, 1993
Cherian MG, Howell SB, Imura N, et al.: Role of metallothionein in carcinogenesis. Toxicol Appl Pharmacol 126: 1–5, 1994
Fan LZ, Cherian MG. Potential role of p53 on metallothionein induction in human epithelial breast cancer cells. Br J Cancer 87: 1019–1026, 2002.
Schwarz MA, Lazo JS, Yalowich JC, et al.: Metallothionein protects against the cytotoxic and DNA-damaging effects of nitric oxide. Proc Natl Acad Sci USA 92: 4452–4456, 1995.
Andrews GK, Adamson ED, Gedamu L: The ontogeny of expression of murine metallothionein: comparison with the alpha-fetoprotein gene. Dev Biol 1984; 103: 294–303.
Nagel WW, Vallee BL: Cell cycle regulation of metallothionein in human colonic cancer cells. Proc Natl Acad Sci USA 92:579–583, 1995.
Abdel-Mageed A, Agrawal KC: Antisense down-regulation of metallothionein induces growth arrest and apoptosis in human breast carcinoma cells. Cancer Gene Ther 4: 199–207, 1997.
Gurel V, Sens DA, Somji S, et al.: Stable transfection and overexpression of metallothionein isoform 3 inhibits the growth of MCF-7 and Hs578T cells but not that of T-47D or MDA-MB-231 cells. Breast Cancer Res Treat 80: 181–191, 2003.
Cai L, Wang GJ, Xu ZL, et al.: Metallothionein and apoptosis in primary human hepatocellular carcinoma from northern China. Anticancer Res 18: 4667–4672, 1998.
Jayasurya A, Bay BH, Yap WM, et al.: Correlation of metallothionein expression with apoptosis in nasopharyngeal carcinoma. Br J Cancer 82: 1198–1203, 2000.
Huang J, Tan PH, Thiyagarajan J, et al.: Prognostic significance of glutathione S-transferase-pi in invasive breast cancer. Mod Pathol 16: 558–565, 2003.
Abdel-Mageed A, Agrawal KC: Activation of nuclear factor kappaB: potential role in metallothionein-mediated mitogenic response. Cancer Res 58: 2335–2338, 1998.
Sakurai A, Hara S, Okano N, et al.: Regulatory role of metallothionein in NF-kappaB activation. FEBS Lett 455:55–58, 1999.
Butcher HL, Kennette WA, Collins O, et al.: Metallothionein mediates the level and activity of nuclear factor ppaB (NFkB) in murine fibroblasts. J Pharmacol Exp Ther 2004 Mar 23 [Epub ahead of print]
Kim CH, Kim JH, Lee J, et al.: Zinc-induced NF-kappaB inhibition can be modulated by changes in the intracellular metallothionein level. Toxicol Appl Pharmacol 190: 189–196, 2003.
Cui Y, Wang J, Zhang X, et al.: ECRG2, a novel candidate of tumor suppressor gene in the esophageal carcinoma, interacts directly with metallothionein 2A and links to apoptosis. Biochem Biophys Res Commun 302:904–915, 2003.
Hainaut P, Mann K: Zinc binding and redox control of p53 structure and function. Antioxid Redox Signal 3: 611–623, 2001.
Meplan C, Richard MJ, Hainaut P: Metalloregulation of the tumor suppressor protein p53: zinc mediates the renaturation of p53 after exposure to metal chelators in vitro and in intact cells. Oncogene 19: 5227–5236, 2000.
Jacob C, Maret W, Vallee BL: Control of zinc transfer between thionein, metallothionein, and zinc proteins. Proc Natl Acad Sci USA 95: 3489–3494, 1998.
Haerslev T, Jacobsen GK, Zedeler K: The prognostic significance of immunohistochemically detectable metallothionein in primary breast carcinomas. APMIS 103: 279–285, 1995.
Oyama T, Take H, Hikino T, et al.: Immunohistochemical expression of metallothionein in invasive breast cancer in relation to proliferative activity, histology and prognosis. Oncology 53: 112–117, 1996.
Ioachim E, Kamina S, Demou A, et al.: Immunohistochemical localization of metallothionein in human breast cancer in comparison with cathepsin D, stromelysin-1, CD44, extracellular matrix components, P53, Rb, C-erbB-2, EGFR, steroid receptor content and proliferation. Anticancer Res 19: 2133–2139, 1999.
Goulding H, Jasani B, Pereira H, et al.: Metallothionein expression in human breast cancer. Br J Cancer 72: 968–972, 1995.
Douglas-Jones AG, Navabi H, Morgan JM, et al.: Immunoreactive p53 and metallothionein expression in duct carcinoma in situ of the breast. No correlation. Virchows Arch 430: 373–379, 1997.
Jin R, Bay BH, Chow VT, et al.: Metallothionein 1E mRNA is highly expressed in oestrogen receptor-negative human invasive ductal breast cancer. Br J Cancer 83: 319–323, 2000.
Cree IA, Knight L, Di Nicolantonio F, et al.: Chemosensitization of solid tumors by modulation of resistance mechanisms. Curr Opin Investig Drugs 3: 634–640, 2002.
Kishi K, Doki Y, Miyata H, et al.: Prediction of the response to chemoradiation and prognosis in oesophageal squamous cancer. Br J Surg 89:597–603, 2002.
Siu LL, Banerjee D, Khurana RJ, et al.: The prognostic role of p53, metallothionein, P-glycoprotein, and MIB-1 in muscleinvasive urothelial transitional cell carcinoma. Clin Cancer Res 4: 559–565, 1998.
Joseph MG, Banerjee D, Kocha W, et al.: Metallothionein expression in patients with small cell carcinoma of the lung: correlation with other molecular markers and clinical outcome. Cancer 92: 836–842, 2001.
Andrews PA, Murphy MP, Howell SB. Metallothionein-mediated cisplatin resistance in human ovarian carcinoma cells. Cancer Chemother Pharmacol 19: 149–154, 1987.
Germain I, Tetu B, Brisson J, et al.: Markers of chemoresistance in ovarian carcinomas: an immunohistochemical study of 86 cases. Int J Gynecol Pathol 15: 54–62, 1996.
Wrigley E, Verspaget HW, Jayson GC, et al.: Metallothionein expression in epithelial ovarian cancer: effect of chemotherapy and prognostic significance. J Cancer Res Clin Oncol 126: 717–721, 2000.
Shimoda R, Achanzar WE, Qu W, et al.: Metallothionein is a potential negative regulator of apoptosis. Toxicol Sci 73: 294–300, 2003.